BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 26718527)

  • 1. Pancreatic neuroendocrine tumors: A single-center 20-year experience with 100 patients.
    Shiba S; Morizane C; Hiraoka N; Sasaki M; Koga F; Sakamoto Y; Kondo S; Ueno H; Ikeda M; Yamada T; Shimada K; Kosuge T; Okusaka T
    Pancreatology; 2016; 16(1):99-105. PubMed ID: 26718527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological Findings and Treatment Outcomes of Patients with Primary Hepatobiliary Neuroendocrine Neoplasms: A Retrospective Single-institution Analysis.
    Komiyama S; Okusaka T; Maruki Y; Ohba A; Nagashio Y; Kondo S; Hijioka S; Morizane C; Ueno H; Sukeda A; Mizui T; Takamoto T; Nara S; Ban D; Esaki M; Hiraoka N; Shimada K
    Intern Med; 2024 Apr; 63(7):891-901. PubMed ID: 37612088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification.
    Deng BY; Liu F; Yin SN; Chen AP; Xu L; Li B
    Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):261-268. PubMed ID: 29307515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis of clinicopathological characteristics, therapeutic strategy and prognosis of 501 patients with gastric neuroendocrine neoplasms attending a single center].
    Zhang BL; Lu YX; Liang WQ; Gao YH; Xi HQ; Wang XX; Zhang KC; Chen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):459-466. PubMed ID: 37217354
    [No Abstract]   [Full Text] [Related]  

  • 5. Surgical treatment and prognosis of gastric neuroendocrine neoplasms: a single-center experience.
    Shen C; Chen H; Chen H; Yin Y; Han L; Chen J; Tang S; Yin X; Zhou Z; Zhang B; Chen Z
    BMC Gastroenterol; 2016 Sep; 16(1):111. PubMed ID: 27613657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinicopathologic characteristics and prognosis of rectal neuroendocrine neoplasms].
    Liu T; Liu P; Wu T; Pan Y; Chen G; Wang P; Jiang Y; Wu Y; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1015-1019. PubMed ID: 28900992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms.
    Mizuno Y; Kudo A; Akashi T; Akahoshi K; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Tanaka S; Tateishi U; Tanabe M
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1155-1163. PubMed ID: 29602973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinicopathological features of pancreatic neuroendocrine neoplasms: a retrospective analysis of 64 cases].
    Yao W; Wang W; Li G
    Zhonghua Zhong Liu Za Zhi; 2014 Apr; 36(4):287-93. PubMed ID: 24989916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
    Tang LH; Basturk O; Sue JJ; Klimstra DS
    Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinicopathological characteristics and prognosis analysis of colorectal neuroendocrine neoplasms based on the data from domestic six medical centers].
    Zhang Y; Peng X; Jin K; Wang W; Feng X; Zeng Y; Chen M; Yu X; Chen Y; Chen J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1235-1240. PubMed ID: 27928792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
    Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinicopathological classification and prognostic factors of gastrointestinal neuroendocrine neoplasms: an analysis of 119 cases].
    Ma X; Zhao W; Zhuang C; Wang X; Tu L; Wang M; Sun Y; Cao H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):997-1001. PubMed ID: 28900989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival Analyses for Patients With Surgically Resected Pancreatic Neuroendocrine Tumors by World Health Organization 2010 Grading Classifications and American Joint Committee on Cancer 2010 Staging Systems.
    Yang M; Ke NW; Zhang Y; Zeng L; Tan CL; Zhang H; Mai G; Tian BL; Liu XB
    Medicine (Baltimore); 2015 Dec; 94(48):e2156. PubMed ID: 26632896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.
    Heetfeld M; Chougnet CN; Olsen IH; Rinke A; Borbath I; Crespo G; Barriuso J; Pavel M; O'Toole D; Walter T;
    Endocr Relat Cancer; 2015 Aug; 22(4):657-64. PubMed ID: 26113608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.
    Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O
    Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of World Health Organization 2010 Classification for Gastroenteropancreatic Neuroendocrine Neoplasms with the Prognosis of Ovarian Neuroendocrine Neoplasms: Kansai Clinical Oncology Group-Protocol Review Committee/Intergroup Study.
    Kai K; Nasu K; Nishida H; Daa T; Shikama A; Shiozaki T; Kurakazu M; Yano M; Imamura Y; Tokunaga H; Tasaki K; Iida Y; Yamada Y; Morisawa H; Nakagawa S; Fujimoto E; Tsuruta T; Matsumoto H; Arakawa A; Nonaka M; Takano H; Ushiwaka T; Mori T; Ito K; Motohashi T; Teramoto N; Yamada T
    Neuroendocrinology; 2021; 111(4):320-329. PubMed ID: 32097950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
    J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: Comparison of gastro-enteric and pancreatic locations.
    Russolillo N; Vigano' L; Razzore P; Langella S; Motta M; Bertuzzo F; Papotti M; Ferrero A
    Eur J Surg Oncol; 2015 Jun; 41(6):751-7. PubMed ID: 25887286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the World Health Organization 2010 grading system in surgical outcome and prognosis of pancreatic neuroendocrine tumors.
    Yang M; Tian BL; Zhang Y; Su AP; Yue PJ; Xu S; Wang L
    Pancreas; 2014 Oct; 43(7):1003-8. PubMed ID: 24945681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
    Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
    Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.